Are microRNAs suitable biomarkers of immunity to tuberculosis?

The crucial role of miRNAs in the regulation of immunity e.g. against infections is generally accepted. But do miRNAs also qualify as biomarkers in this context? Given the strict prerequisites of biomarkers that should reliably indicate (or predict) biological conditions [1], the applicability of miRNAs as biomarkers cannot be taken for granted. Importantly, the aim to identify biomarkers has also major implications on the study design. Especially, definition and characterization of study groups and samples in human studies are demanding and verification of biomarker candidates strongly depends on the comparability of different studies in this regard. Against this background, our mini-review aims to (i) summarize the current state of research on miRNAs as biomarkers in tuberculosis, (ii) evaluate study designs and comparability of biomarker studies, and (iii) point out minimal requirements and strategies to identify biomarkers.

Mycobacterium tuberculosis (M. tuberculosis), the causative agent of human tuberculosis, is still a major threat to humankind. About 8 million new cases and more than 1.3 million deaths annually place tuberculosis among the top three fatal infections [2]. However, the vast majority of M. tuberculosis-infected individuals is capable of controlling the pathogen. These latently M. tuberculosis-infected (LTBI) individuals remain infected probably for lifetime. Diagnosis of tuberculosis and discrimination from LTBI in children are challenging because of the lack of clinical signs and imaging findings. Immunological tests (i.e. IFNγ release assays and tuberculin skin test) do also not discriminate active tuberculosis and LTBI. Since treatment regimen differs depending on the diagnosis, biomarkers for classification would be of great practical value. Protection against progression towards active disease is strongly dependent on an effective immune surveillance. Cellular immunity, especially CD4⁺ T cells and macrophages, are crucial players in this highly orchestrated host-pathogen interaction. The risk of adult LTBI to develop active tuberculosis is up to 10% per lifetime (with the majority of progression events occurring within the first two years; about 5%). Of note, infants and young children are highly susceptible to tuberculosis with untreated progression rates of up to 40% within the first year of infection. Biomarkers that reliably predict disease progression of LTBI would allow preventive treatment of highly susceptible individuals as it is done for young children. This way, the number of individuals that become infectious could be greatly reduced. As a consequence, also the number of `new' LTBIs would decrease, a decisive step for eradication of tuberculosis.

A long treatment regimen about 6 to 9 months is necessary to cure tuberculosis patients. In addition, multidrug-resistant (MDR) M. tuberculosis strains complicate treatment courses. Especially insufficient adherence to chemotherapy against tuberculosis is a major problem in high incidence countries leading to treatment failure, development of MDR, as well as spread of M. tuberculosis infections. Shortened treatment e.g. by novel drugs or combination of existing medication would largely improve this situation and biomarkers that predict successful treatment could catalyze this process significantly. In childhood tuberculosis, prediction of effective treatment is particularly difficult since detection of M. tuberculosis in sputum fails in the majority of cases. Reduced pathogen load—defined by sputum conversion in adult tuberculosis patients and a hallmark for treatment efficacy—is therefore not definable in the majority of children. Moreover, bacterial load at treatment onset is expected to be lower in children than in adults. Biomarkers indicating bacterial load could contribute to the development of shorter treatment regimens.

Protective immunity against M. tuberculosis is predominantly based on the T-helper type 1 (T_H1) mediated cellular arm of the host immune response and the fine-tuned interaction of T_H1 cells with M. tuberculosis-infected macrophages. T-helper cell differentiation and plasticity was shown to be tightly regulated by miRNAs [3] and the same holds true for macrophages, the M. tuberculosis host cell population [4]. Therefore, the relevance of miRNAs for immune regulation in infectious diseases can be taken for granted.

The processes underlying the generation and regulation of miRNAs are reviewed in detail elsewhere [5]. In brief, miRNAs inhibit mRNA translation leading to mRNA target degradation and decreased protein expression. Several miRNA families regulate immune processes. miR-29, e.g., was shown to inhibit IFNγ expression of T cells [6]. miR-29 was able to block increased IFNγ levels, a typical feature of general miRNA knockout mice, and over-expression of miR-29 increased susceptibility to tuberculosis [6]. miR-21 was shown to be upregulated in macrophages after contact with Mycobacterium bovis BCG [7]. Wu et al. demonstrated miR-21-mediated inhibition of interleukin-12 in macrophages and, additionally, found increased apoptosis in dendritic cells due to miR-21 inhibition of bcl-2 [7]. They conclude that mycobacteria induce expression of miR-21 leading to impaired classical macrophage activation and dependent T_H1 immunity. The mechanisms how mycobacteria interfere with host miRNA expression remain elusive. miR-155 has been intensively studied with regard to its role in immunity [8]. Macrophages infected with M. tuberculosis show differential miR-155 expression [9],[10] and Kumar et al. identified the M. tuberculosis early secreted antigenic factor 6 (ESAT-6) as a crucial factor in this process [10]. The role of miR-155 in the interaction between macrophages and mycobacteria may have different aspects: interference with mycobacterial dormancy and inflammatory mediators (i.e. IL-6 and cyclooxygenase-2) [10]. Recently, Wang et al. demonstrated that miR-155 is involved in autophagy, an essential process of mycobacterial killing in host macrophages [11]. Taken together, previous studies strongly suggest a role of miRNAs in host immunity against tuberculosis.

For application as biomarkers of course, miRNA candidates must be detectable in surrogate tissue and availability of samples has to be ensured especially in tuberculosis endemic countries. Application of surrogate tissues/cells/body fluids comprises inherent jeopardy (i.e. differential cellular composition of blood or serum) that may confound results [1],[12]. Hence, single biomarker or biomarker signatures must be robust enough to define or predict e.g. disease stages, treatment efficacy, or susceptibility despite of natural variability. To estimate the informative values of miRNA as biomarkers, several studies performed comparative expression analysis mainly in peripheral blood and sputum samples. These studies comprised global approaches to determine multiple miRNAs or measurement of single miRNA candidates. Results of these studies are discussed in the next chapters.

Peripheral blood and derived cell populations are frequently used for biomarker discovery and e.g. quantification of T-cell subpopulation proportions already made its way into clinical routine diagnostics of HIV/AIDS. In tuberculosis, candidate- and array-based global approaches were applied for miRNA analyses of peripheral blood and derived cells. An overview of miRNA biomarker studies and resulting candidates is provided in Table 1. The majority of studies focused on comparisons between patients with active TB, LTBIs, as well as non-M. tuberculosis-infected (TSTneg) controls. Wang et al. determined expression profiles of 955 miRNAs (human and human-viral) of enriched peripheral blood mononuclear cells (PBMCs) from TB patients and contacts with or without latent M. tuberculosis infection. Classification analyses did not discriminate between study groups but this may be due to small study group sizes [13]. Of 451 detectable miRNAs, a cluster of 17 miRNAs showed significant differences between active TB and M. tuberculosis-infected contacts (Table 1) [13]. Spinelli et al. used a candidate gene approach to determine expression of six miRNAs in PBMCs of TB patients and TSTneg individuals [14]. This study detected miR-424 to be upregulated in TB patients from both studies whereas no difference for miR-223 was found [14]. Detailed analyses of miR-223 have been performed by Dorhoi et al. who detected lower expression of miR-223 in PBMCs of TB patients as compared to LTBI and higher expression as compared to TSTneg [15]. Comparisons of pulmonary tissue samples revealed increased miR-223 expression in the lung of TB patients as compared to healthy controls [15]. Contrary findings for peripheral blood may therefore indicate differential migration activity of miR-223-expressing cells to affected tissue sites at different disease stages. Therefore, although miR-223 likely plays an important role in host immunity against TB, it may not qualify as a biomarker in surrogate tissue.

miR-144* was mentioned as a candidate regulator or IFN-γ expression before. Liu et al. performed global miRNA analysis of PBMCs from TB patients and healthy controls (three individuals per study group) [16]. This study identified 30 differentially regulated miRNAs but decided to focus on increased miR-144 expression in TB patients [16]. However, contrary findings with regard to miR-144* expression have been published. Wang et al. also found increased miR-144* expression in TB patients (only in comparison to TSTneg) [13] whereas no differential miR-144 expression was found by others [14]. Since miR-144* was described as an important T-cell factor in TB, different results may be due to confounding effects of cellular heterogeneity in peripheral blood [12]. Consequently, we and others performed miRNA expression analysis in enriched CD4⁺ T cells [17],[18]. Kleinsteuber et al. analyzed miR-144* expression in CD4⁺ T cells but since it was not detectable in a subgroup of donors, miR-144* was excluded from further analyses [18]. In addition, a global miRNA array-based approach detected decreased miR-144 expression of CD4⁺ T cells in TB patients as compared to LTBI but these results of pooled sample analyses were not verified by quantitative PCR [17]. The same study focused on another promising candidate, namely miR-29, that was increased in CD4⁺ T cells from TB patients (compared to LTBI and TSTneg) [17]. In contrast, Kleinsteuber et al. detected decreased miR-29a of CD4⁺ T cells from TB patients compared to LTBI (but not TSTneg) [18]. Taken together, as for miR-223, a role for miR-144 and miR-29 in host immunity against TB is likely but the applicability of miR-29 as a biomarker has not been proven.

So far, only one study has been performed determining miRNA expression profiles of children with TB and LTBI [18]. Kleinsteuber et al. analyzed differentially expressed candidates of CD4⁺ T cells from adult TB patients. This study confirmed significant downregulation of miR-26a, miR-29a, and miR-142-3p in peripheral blood of children with TB compared to children with LTBI. In addition, a tendency of increased miR-26a, miR-29a, and miR-142-3p expression after recovery was found [18]. Nevertheless, the study of Kleinsteuber et al. also demonstrated marked interindividual differences of miRNA candidate expression (up to 10⁵-fold). This finding generally questions the applicability of miRNA as robust biomarkers for discrimination. At least, one would have to apply miRNA expression pattern of several miRNA, but studies that have sufficient statistical power are not available.

In conclusion, several data- or hypothesis-driven studies have been performed to identify miRNAs as surrogate tissue biomarkers in peripheral blood but highly promising candidates have not been identified.

Various studies identified miRNAs in human plasma associated with defined structures (i.e. exosomes and microvesicles apoptotic bodies) that are not degraded by plasma enzymes. There is arising evidence that circulating miRNAs exert biological functions e.g. as part of intercellular communication, and may be used as biomarkers for human diseases [19]. The appeal of using plasma miRNAs in clinical applications is high, as separation and preservation of plasma or serum samples is clinical routine also in M. tuberculosis endemic countries. However, variations in preanalytical processing of samples and lack of established endogenous controls limit the comparability of results [21].

So far, five studies have been performed to identify plasma miRNAs that distinguish between patients with pulmonary TB, LTBI, and TSTneg as well as other infections or malignant diseases. An overview and comparison of the results concerning discrimination between pulmonary TB and healthy subjects is given in Table 2. Fu et al. screened pooled serum samples of patients with pulmonary TB and matched healthy controls for differential expression of 1,223 miRNAs [20]. They identified 92 differentially expressed miRNAs (59 upregulated and 33 downregulated in TB patients). Three of these candidates were validated by qPCR in individual samples, but none of these three could be confirmed in later studies. Two differentially expressed candidates, i.e. miR-29a and miR-93*, were also assessed in sputum of the same patients. Notably, increased miR-29a expression was detected in sputum of TB patients. The same group investigated miRNA expression patterns of sputum in a second cohort and confirmed differential expression of miR-29a [21].

Qi et al. compared sera of TB patients to healthy controls and patients with other diseases [22]. Overall, 667 miRNAs were determined in serum pools of TB patients and healthy controls by microarray analysis. This study identified 97 differentially expressed miRNAs and selected a set of ten for verification by quantitative PCR. A set of three miRNAs, i.e. miR-361-5p, miR-889, and miR-576-3p, was identified that specifically indicated TB disease. Differential expression of these candidate miRNAs was not found by any other study. Abd-el-Fattah et al. performed microarray-based analysis and validated results by qPCR to identify miRNAs for discrimination between pulmonary TB, pneumonia, lung cancer, pleural transudate, and matched controls [23]. In this study, a combination of increased miR-182 and miR-197 expression was found to be specific for TB. Correspondingly, Qi et al. also detected over-expression of miR-197 in TB patients [22].

Miotto et al. recruited two patient cohorts: (i) children with TB, TB/HIV co-infection and controls in Tanzania and Uganda as well as (ii) adult patients with TB (pulmonary and extra-pulmonary), LTBI, or other pulmonary infections and healthy controls in Italy [24]. This study compared array-based expression patterns of 671 miRNAs using sample pools of ten patients and 18 sex-matched individuals from the different subgroups. A cluster of 15 miRNAs distinguished between pulmonary TB and healthy controls. Within this set of markers, miR-192 was the only candidate significantly differentially expressed between the adult and the pediatric study groups. Comparing these results to the study of Qi et al., three miRNAs (miR-25, miR-590-5p, miR-885-5p) were found concordantly and let-7e disconcordantly regulated. Discrepancies may be due to different methods e.g. different endogenous controls used. Qi et al. used miR-16 as endogenous that has been found to be regulated by others [24].

Zhang et al. applied deep sequencing on serum samples between groups of patients with TB, pneumonia, chronic obstructive pulmonary disease, and lung cancer and healthy controls [25]. They identified a set of 15 differentially expressed miRNAs and a subset of six; namely, miR-378, miR-483-5p, miR-22, miR-29c, miR-101, and miR-320b classified the TB patients study group. miR-483-5p and miR-22 were also regulated concordantly in the study by Fu et al. whereas miR-101 was not different [20]. No differences for miR-29c were found in the study by Miotto et al. [24]. In conclusion, even some overlap of differentially expressed miRNAs between the studies existed; a common miRNA or miRNA pattern that classified TB patients was not found. miR-22, miR-25, miR-197, miR-365, miR-483-5p, miR-590-5p, and miR-885-5p are yet the most promising candidates since these miRNAs were validated for discrimination of TB and healthy controls in two studies (see Table 2).

As a consequence, future biomarker studies should adhere to minimal prerequisites for conformity of study designs, case/control definitions, analytical settings, and data evaluation to ensure comparability of results. Table 3 summarizes some key points that should be considered for biomarker studies and highlights possible strategies and approaches to circumvent common pitfalls. Consideration of these points for the design and evaluation of biomarker studies will improve comparability of future studies and may lead to identification of suitable miRNA biomarkers.